<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136011">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01686880</url>
  </required_header>
  <id_info>
    <org_study_id>TRYPHON</org_study_id>
    <nct_id>NCT01686880</nct_id>
  </id_info>
  <brief_title>Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver</brief_title>
  <acronym>TRYPHON</acronym>
  <official_title>Treatment With Yttrium90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jules Bordet Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jules Bordet Institute</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety of transarterial radioembolization prior
      to surgical resection or radiofrequency in cirrhotic patients with hepatocellular carcinoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess the peri-operative morbidity and mortality of
      supraselective ablative transarterial radioembolization prior to surgical resection or
      radiofrequency in cirrhotic patients with HCC
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Peri-operative morbidity</measure>
    <time_frame>3 months after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>peri-operative morbidity of supraselective ablative transarterial radioembolization prior to surgical resection or radiofrequency in cirrhotic patients with HCC (starting from date of inclusion till 90 days after surgery or hospital discharge if more than 90 days)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of the overall disease free survival and Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One and three years survival</measure>
    <time_frame>one and three years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimation of disease free survival and overall survival rates after 1 and 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor regression</measure>
    <time_frame>8 weeks after Trans-arterial radioembolization</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of tumour size regression after Trans-arterial radioembolization by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Imaging</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of imaging parameters changes (DW-MRI, FDG-PET/CT) and MAA-SPECT-CT in relation to the outcome measured by tumour regression after TARE, disease free and overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contra-lateral Lobe Hypertrophy</measure>
    <time_frame>3 Years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of TARE induced liver contralateral lobe hypertrophy (volumetric measurement by MRI).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Preoperative aTARE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients in this arm will receive Sirsphere trans-arterial radioembolization before surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sirsphere trans-arterial radioembolization</intervention_name>
    <description>Patients will receive Sirsphere trans-arterial radioembolization before surgery</description>
    <arm_group_label>Preoperative aTARE</arm_group_label>
    <other_name>TARE</other_name>
    <other_name>SIRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years.

          -  Cirrhotic liver demonstrated by typical liver dysmorphy on imaging and/or liver
             biopsy.

          -  HCC  with at least one lesion measuring more than 1 cm in diameter with a single
             dynamic imaging technique (CT or MRI), showing intense arterial uptake followed by
             washout of contrast in the venous-delayed phases, or diagnosed by biopsy.

          -  Borderline resectable disease eligible for surgical resection or radiofrequency
             destruction.

          -  No extra-hepatic dissemination.

          -  ECOG Performance status &lt; 2.

          -  Women of child-bearing potential must agree to use adequate contraception (hormonal
             or barrier method of birth control, abstinence) prior to study entry and for the
             duration of study participation. Should a woman become pregnant or suspect she is
             pregnant while participating in this study, she should inform her treating physician
             immediately.

          -  Signed written informed consent (approved by an Independent Ethics Committee)
             obtained prior to any study specific baseline procedures.

        Exclusion Criteria:

          -  Decompensated cirrhosis (Child Pugh B, C).

          -  Extra-hepatic tumour spread.

          -  Previous or concomitant malignancies within five years other than basal cell
             carcinoma of the skin.

          -  Pregnancy, lactation or refusal to use adequate contraceptive measures (hormonal or
             barrier method of birth control, abstinence).

          -  Pre-existing other hepatic disease (liver abscess, hepatic sarcoidosis or
             tuberculosis, sclerosing cholangitis, …).

          -  Previous trans-arterial radioembolization (TARE).

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition of the administered materials.

          -  Bleeding diathesis, history of cardiovascular ischemic disease or cerebrovascular
             incident within the last six months.

          -  Major surgery within four weeks.

          -  Uncontrolled concurrent illness including, but not limited to ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Uncontrolled Diabetes.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Hendlisz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Jules Bordet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vincent Donckier, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasme University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alain Hendlisz, MD</last_name>
    <phone>+32 0 2 541 35 41</phone>
    <email>alain.hendlisz@bordet.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vincent Donckier, MD, PhD</last_name>
    <phone>+32 2 541 72 92</phone>
    <email>vincent.donckier@erasme.ulb.ac.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alain Hendlisz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amélie Deleporte, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Flamen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe Delatte, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hazem El Mansy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasme Hosptial</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vincent Donckier, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valerio Lucidi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Luc Van Laethem, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Antonietta Bali, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe Moreno, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis Brisbois, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Delphine Degre, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pieter Demetter, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.bordet.be/</url>
    <description>Jules Bordet Institute</description>
  </link>
  <link>
    <url>http://www.erasme.ulb.ac.be/</url>
    <description>Erasme Hospital</description>
  </link>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 20, 2013</lastchanged_date>
  <firstreceived_date>September 11, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Liver Cirrhosis</keyword>
  <keyword>radioembolization</keyword>
  <keyword>SIRT</keyword>
  <keyword>TARE</keyword>
  <keyword>Sirspheres</keyword>
  <keyword>neoadjuvant</keyword>
  <keyword>liver cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
